# Johnson & Johnson (JNJ) financials

Johnson & Johnson reported revenue of $94.2 billion for fiscal year 2025 (the twelve months to 28 Dec 2025), up 6.0% from fiscal 2024. Net income was $26.8 billion and diluted earnings per share $11.03.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 27 Sep 2026), revenue was $25.4 billion, up 5.9% from a year earlier.

Source: Johnson & Johnson's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 21 Oct 2026. Amounts in USD. Page: https://aapwire.com/stocks/JNJ. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Johnson & Johnson reported revenue of $25.4 billion, up 5.9% from a year earlier, net income of $210 million and diluted earnings per share of $0.09 against $2.12 for the third quarter of fiscal 2026 (the three months to 27 Sep 2026).

From its quarterly report, the results first announced on 13 Oct 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $25.40B | $23.99B | +5.9% |
| Gross profit | $17.30B | $16.69B | +3.7% |
| Gross margin | 68.1% | 69.6% | −1.4 pts |
| Operating income | $5.84B | $7.03B | −16.9% |
| Operating margin | 23.0% | 29.3% | −6.3 pts |
| Net income | $210.0M | $5.15B | −95.9% |
| Diluted EPS | $0.09 | $2.12 | −95.8% |
| Operating cash flow | $7.72B | $9.17B | −15.8% |
| Capital expenditure | $1.36B | $1.16B | +17.7% |
| Free cash flow | $6.36B | $8.01B | −20.6% |

Page: https://aapwire.com/stocks/JNJ/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $71.89B | $76.45B | $81.58B | $82.06B | $82.58B | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B |
| Revenue growth | +2.6% | +6.3% | +6.7% | +0.6% | +0.6% | −4.7% | +1.6% | +6.5% | +4.3% | +6.0% |
| Gross profit | $50.10B | $51.01B | $54.49B | $54.50B | $54.16B | $55.34B | $55.39B | $58.61B | $61.35B | $63.94B |
| Operating income | $20.37B | $18.18B | $19.80B | $19.81B | $19.49B | $19.83B | $19.95B | $21.21B | $20.80B | $25.29B |
| Net income | $16.54B | $1.30B | $15.30B | $15.12B | $14.71B | $20.88B | $17.94B | $35.15B | $14.07B | $26.80B |
| Diluted EPS | $5.93 | $0.47 | $5.61 | $5.63 | $5.51 | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
| Operating cash flow | $18.77B | $21.06B | $22.20B | $23.42B | $23.54B | $23.41B | $21.19B | $22.79B | $24.27B | $24.53B |
| Capital expenditure | $3.23B | $3.28B | $3.67B | $3.50B | $3.35B | $3.65B | $4.01B | $4.54B | $4.42B | $4.83B |
| Free cash flow | $15.54B | $17.78B | $18.53B | $19.92B | $20.19B | $19.76B | $17.18B | $18.25B | $19.84B | $19.70B |
| Gross margin | 69.7% | 66.7% | 66.8% | 66.4% | 65.6% | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Operating margin | 28.3% | 23.8% | 24.3% | 24.1% | 23.6% | 25.2% | 24.9% | 24.9% | 23.4% | 26.8% |
| Net margin | 23.0% | 1.7% | 18.8% | 18.4% | 17.8% | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% |
| Cash and equivalents | $18.97B | $17.82B | $18.11B | $17.30B | $13.98B | $14.49B | $12.89B | $21.86B | $24.11B | $19.71B |
| Total debt | $28.83B | $36.08B | $33.08B | $28.69B | $38.16B | $36.88B | $42.49B | $31.90B | $39.58B | $51.33B |
| Shareholders' equity | $70.42B | $60.16B | $59.75B | $59.47B | $63.28B | $74.02B | $76.80B | $68.77B | $71.49B | $81.54B |
| Diluted shares | 2.8B | 2.7B | 2.7B | 2.7B | 2.7B | 2.7B | 2.7B | 2.6B | 2.4B | 2.4B |
| Dividends per share | $3.15 | $3.32 | $3.54 | $3.75 | $3.98 | $4.19 | $4.45 | $4.70 | $4.91 | $5.14 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B | $24.06B | $25.31B | $25.40B |
| Revenue, year on year | +5.3% | +2.4% | +5.8% | +6.8% | +9.1% | +9.9% | +6.6% | +5.9% |
| Gross margin | 68.3% | 66.4% | 67.9% | 69.6% | 67.6% | 66.3% | 68.2% | 68.1% |
| Operating income | $3.58B | $6.18B | $6.65B | $7.03B | $5.43B | $6.33B | $7.14B | $5.84B |
| Net income | $3.43B | $11.00B | $5.54B | $5.15B | $5.12B | $5.24B | $5.53B | $210.0M |
| Diluted EPS | $1.41 | $4.54 | $2.29 | $2.12 | $2.09 | $2.14 | $2.27 | $0.09 |
| Free cash flow | $5.37B | $3.38B | $2.83B | $8.01B | $5.47B | $1.47B | $7.29B | $6.36B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [MedTech worldwide operational sales (change on a year)](https://aapwire.com/stocks/JNJ/kpi/medtech-worldwide-operational-sales-change-on-a-year) | 2.5% | quarter to 27 Sep 2026 | down 3.1 points |
| [Oncology revenue](https://aapwire.com/stocks/JNJ/kpi/oncology-revenue) | $7.6B | quarter to 27 Sep 2026 | up 16.4% |
| [Immunology revenue](https://aapwire.com/stocks/JNJ/kpi/immunology-revenue) | $4.2B | quarter to 27 Sep 2026 | up 1.3% |
| [Neuroscience revenue](https://aapwire.com/stocks/JNJ/kpi/neuroscience-revenue) | $2.4B | quarter to 27 Sep 2026 | up 17.3% |
| [Cardiovascular revenue](https://aapwire.com/stocks/JNJ/kpi/cardiovascular-revenue) | $2.3B | quarter to 27 Sep 2026 | up 4.2% |
| [Pulmonary Hypertension revenue](https://aapwire.com/stocks/JNJ/kpi/pulmonary-hypertension-revenue) | $897.0M | quarter to 27 Sep 2026 | down 19.6% |
| [Cardiovascular/Metabolism/Other revenue](https://aapwire.com/stocks/JNJ/kpi/cardiovascular-metabolism-other-revenue) | $849.0M | quarter to 27 Sep 2026 | down 5.6% |
| [Infectious Diseases revenue](https://aapwire.com/stocks/JNJ/kpi/infectious-diseases-revenue) | $813.0M | quarter to 27 Sep 2026 | down 1.9% |
| [Shockwave revenue](https://aapwire.com/stocks/JNJ/kpi/shockwave-revenue) | $325.0M | quarter to 27 Sep 2026 | up 16.9% |
| [Innovative Medicine revenue](https://aapwire.com/stocks/JNJ/kpi/innovative-medicine-revenue) | $16.8B | quarter to 27 Sep 2026 | up 7.7% |
| [MEDTECH revenue](https://aapwire.com/stocks/JNJ/kpi/medtech-revenue) | $8.6B | quarter to 27 Sep 2026 | up 2.5% |
| [United States revenue](https://aapwire.com/stocks/JNJ/kpi/united-states-revenue) | $15.0B | quarter to 27 Sep 2026 | up 9.1% |
| [Non-US revenue](https://aapwire.com/stocks/JNJ/kpi/non-us-revenue) | $10.4B | quarter to 27 Sep 2026 | up 1.5% |
| [Europe revenue](https://aapwire.com/stocks/JNJ/kpi/europe-revenue) | $5.4B | quarter to 27 Sep 2026 | down 0.6% |
| [Asia-Pacific, Africa revenue](https://aapwire.com/stocks/JNJ/kpi/asia-pacific-africa-revenue) | $3.7B | quarter to 27 Sep 2026 | up 1.0% |
| [Western Hemisphere, excluding U.S. revenue](https://aapwire.com/stocks/JNJ/kpi/western-hemisphere-excluding-u-s-revenue) | $1.4B | quarter to 27 Sep 2026 | up 12.5% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
